HCV therapy and risk of liver cancer recurrence: who to treat?

Massimo Colombo^{1

2}, Vincenzo Boccaccio³

Affiliations

¹ Center for Translational Research in Hepatology, Humanitas hospital and Humanitas Clinical and Research Center, Rozzano, Italy. mcolombo46@yahoo.it.
² Department of Medicine, Humanitas hospital and Humanitas Clinical and Research Center, Rozzano, Italy. mcolombo46@yahoo.it.
³ Department of Medicine, Humanitas hospital and Humanitas Clinical and Research Center, Rozzano, Italy.

Comment

Massimo Colombo et al. Nat Rev Gastroenterol Hepatol. 2018 Jul.

. 2018 Jul;15(7):392-393.

doi: 10.1038/s41575-018-0018-5. Epub 2018 May 11.

Massimo Colombo^{1

2}, Vincenzo Boccaccio³

¹ Center for Translational Research in Hepatology, Humanitas hospital and Humanitas Clinical and Research Center, Rozzano, Italy. mcolombo46@yahoo.it.
² Department of Medicine, Humanitas hospital and Humanitas Clinical and Research Center, Rozzano, Italy. mcolombo46@yahoo.it.
³ Department of Medicine, Humanitas hospital and Humanitas Clinical and Research Center, Rozzano, Italy.

No abstract available

Comment on

Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Huang AC, et al. Hepatology. 2018 Aug;68(2):449-461. doi: 10.1002/hep.29855. Epub 2018 May 16. Hepatology. 2018. PMID: 29476694 Free PMC article.